logo
  

Roche's SARS-CoV-2 Antibody Test Being Used As Part Of Moderna COVID-19 Vaccine Trials

Swiss drug maker Roche Group (RHHBY) announced Wednesday a partnership with Moderna Inc. to utilise the Elecsys Anti-SARS-CoV-2 S antibody test in Moderna's ongoing mRNA-1273 vaccine research trials.

The company noted that its Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in vaccine trial participants. It will help to establish a correlation between vaccine-induced protection and levels of anti-receptor binding domain or RBD antibodies.

Significantly, Moderna's vaccine triggers antibody response specifically to the RBD of the SARS-CoV-2 spike protein.

According to the company, measuring the quantitative levels of anti-RBD SARS-CoV-2 antibodies using Roche's test will help Moderna to gain valuable insights into the correlation between protection from vaccination and antibody levels. This could play a role in assessing if, or when, an individual needs revaccination, or in helping to answer other clinically relevant questions.

Roche recently received Emergency Use Authorization from the U.S. Food and Drug Administration for the Elecsys Anti-SARS-CoV-2 S antibody test.

Thomas Schinecker, CEO Roche Diagnostics, said, "Roche values the collaboration with Moderna, which has already included the successful use of our qualitative Elecsys Anti-SARS-CoV-2 test, targeting the nucleocapsid protein, in an earlier part of the studies. We are pleased to see that our quantitative Elecsys SARS-CoV-2 S test, which targets the spike protein, is now also being used as part of the Moderna vaccine trials, which could ultimately help to end this pandemic."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream Amazon.com Inc. plans to spend more than $1 billion annually to produce movies that will get a theatrical release, Bloomberg reported, citing people familiar with the matter. The online retailer giant, which acquired movie maker MGM Studios earlier this year for $8.45 billion, is likely to produce between 12 and 15 movies each year for movie theaters.
Follow RTT